Clinical evaluation of intramuscular injection of microencapsulated compound megestrol acetate
Han, Z.Y.; Xiao, R.Q.
International Journal of Gynaecology and Obstetrics the Official Organ of the International Federation of Gynaecology and Obstetrics 22(4): 319-324
1984
ISSN/ISBN: 0020-7292 PMID: 6152804 DOI: 10.1016/0020-7292(84)90091-2Document Number: 407629
A comparative clinical study was undertaken by the Sichuan [China]. Cooperative Research Group for Microencapsulated Contraceptives to assess the efficacy of i.m. microencapsulated megestrol compound as a long-acting contraceptive and to find the optimal dosage as regards efficacy, side effects and menstrual irregularities. The 828 women were divided into 4 groups and injected monthly with 4 different dosage combinations that consisted of megestrol acetate and estradiol valerate; 5298 dosage cycles were observed. Microencapsulation effectively prolonged contraceptive effect of the short-acting agents, reduced the required dosage and lowered the incidence of side effects. A combination of 15 mg megestrol acetate and 5 mg estradiol valerate, as compared to the other 3 regimens, was clinically most acceptable because of the lower incidence of menstrual irregularities.
Document emailed within 0-6 h
